3D CoSeedis™: a new in vitro approach to the COVID-19-related cytokine release syndrome

The cytokine release syndrome (CRS) has been reported to be one of the major factors to cause fatal disease progression in patients suffering from COVID-19. With 3D CoSeedis™, abc biopply has now an in vitro 3D cell culture technology at hand that may offer a new approach to investigate CRS under physiologically more relevant conditions.
The idea behind 3D CoSeedis™ is to use a novel, modular, scaffold-free 3D distance co-culture approach to assess complex, multi-cellular communication pathways. This setup allows to address the question of CRS-inducing potentials of experimental compounds under in vivo-like conditions. Furthermore, using this highly predictive 3D platform will eventually allow the simultaneous test of antiviral endpoints, hence facilitate the current multi-system-based testing procedure.
In a first proposal, the unique co-culture and cell communication features of 3D CoSeedis™ will be used to establish standardized organotypic assays that target cellular crosstalk between cell populations involved in the cytokine release syndrome related to severe and fatal SARS-CoV-2 infections. One basic setup could consist of a co-culture from lung epithelial and endothelial cells, which are then confronted with SARS-CoV-2 virus and human mononuclear cells from peripheral blood (PBMCs) to monitor the response to infection.
Setup for testing the interaction of different cell populations upon acute inflammation or viral infection. Candidates for ‘epithelial cells’ could be cell lines derived from lung cancer or from normal airway epithelium, ‘mesenchymal cells’ may be chosen from endothelial (e.g. HUVEC) or mesenchymal stem cells (MSC).
The suggested 3D co-culture platform will allow long-term follow-up (up to 12 weeks of culture without the need of sub-cultivation) and repeated sampling of culture supernatants without harming the assay.Response to infection and compounds over time would be analyzed in a longitudinal fashion by medium sampling at defined intervals. Analysis would address cytokines secreted into the medium, the load of SARS-CoV-2 particles or viral components (e.g. envelop antigens, RNA), coagulation-related factors, and overall glucose consumption and/or levels of catabolites.
Are you interested to get to know more about the opportunities 3D CoSeedis™ offers in COVID-19 research? Or are you about to set-up an equally complex cell-to-cell communication assay? Please do not hesitate to contact me to learn more about the flexibility 3D CoSeedis™ offers to address those questions.
I am looking forward to hearing from you.

   Best regards

   Marco Leu, PhD
   Sales & Operation
   abc biopply ag

   Direct Email / Phone +41 (0)79 834 95 56


Back to overview

Contact us